Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) will announce its Q2 2022 financial results on August 4, 2022, at 8 a.m. ET. The conference call will allow participants to discuss the operational highlights and financial metrics from the quarter. Interested parties can join via U.S. and international calling options, with a webcast available online. After the call, a replay will be accessible on Intellia's website. The company specializes in genome editing using CRISPR technologies, aiming to develop curative treatments for diseases.

CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financial results and operational highlights in a conference call on August 4, 2022, at 8 a.m. ET.

To join the call:

• U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
• Please visit this link for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 4, 2022, at 12 p.m. ET.

About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatx.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com

Lina Li
Senior Director, Investor Relations and Corporate Communications
+1-857-706-1612
lina.li@intelliatx.com

FAQ

When will Intellia Therapeutics release its Q2 2022 earnings results?

Intellia Therapeutics will release its Q2 2022 earnings results on August 4, 2022, at 8 a.m. ET.

How can I join the Intellia Therapeutics earnings call?

To join the call, U.S. callers should dial 1-833-316-0545 while international callers should dial 1-412-317-5726.

Is there a live webcast for the Intellia Therapeutics earnings call?

Yes, a live webcast of the earnings call will be available through Intellia's website during the call.

Where can I find the replay of the Intellia Therapeutics Q2 earnings call?

The replay of the earnings call will be available on the Events and Presentations page of Intellia's website starting August 4, 2022, at 12 p.m. ET.

What technologies does Intellia Therapeutics focus on?

Intellia Therapeutics focuses on developing therapeutics leveraging CRISPR-based genome editing technologies.